Hemophilia with Movement
We recommend
EAHAD 2024: Fresh results of paradigm5 and 6 studies confirm safety and efficacy of N9-GP
Nonacog beta pegol (N9-GP) is a recombinant factor IX with an extended half-life. Its properties allow for the maintenance of a satisfactorily high level of FIX with intravenous application once a week. At the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), held in early February 2024 in Frankfurt, new findings on this treatment were presented during a satellite symposium by Novo Nordisk.
Physical Activity in Young Men with Hemophilia A
What may influence the inclusion of physical activity in the lifestyle of individuals with…
N9-GP in Previously Treated Pediatric Patients with Hemophilia B – Extended Follow-up
An analysis of extended treatment with nonacog alfa pegol (N9-GP) in pediatric patients with…
Articles on this topic
Physical Activity in Hemophiliacs and How to Ensure it Safely
Physical activity is beneficial − and this holds true for patients with hemophilia as well.…
Subscribe
Conferences news
Go to records
Go to records
Go to records
Most read on this topic
Related topic
Conferences news
Go to records
Go to records
Go to records
Most read on this topic
- Manual Fascial Therapy in Patients with Hemophilic Arthropathy
- Physical Activity in Hemophiliacs and How to Ensure it Safely
- Physiotherapy as Part of Comprehensive Care for People with Hemophilia – Recommendations vs. Reality
- The Role of the Physiotherapist in the Management of Hemophilia – Defining a New Normal
- Prevalence and Clinical Impact of Overweight and Obesity in the Hemophilia Population
- Sport and Programmed Sports Therapy in Hemophiliacs
Related topic